- Home
- Services
- usa massachusetts
- chronic disease
Show results for
Refine by
Chronic Disease Services In Massachusetts
5 services found
Manufactured by:BioT Medical based inPetach Tikva, ISRAEL
Many chronic diseases and acute conditions can be treated effectively by using home-use solutions today. However, the benefits cannot be realized if patients take their medication or use connected devices incorrectly or not at all.Therefore patient adherence, persistence and compliance are highly important. ...
Manufactured by:RareStone Group based inShanghai, CHINA
Chronic kidney disease (CKD) is a non-communicable disease usually caused by diabetes and hypertension. The prevalence of chronic kidney disease in China is reported to be 10.8%, and is predicted to increase in the next decade, especially among rural regions and certain geographic regions. Liver ...
by:MtoZ Biolabs based in, MASSACHUSETTS (USA)
Atopic Dermatitis (AD) is prevalent among children aged 1 to 5 years and a considerable number of patients carry this condition into adulthood. As a chronic inflammatory skin disease, AD often coexists with asthma and rhinitis. At the cellular level, the hallmark of AD is characterized by high serum IgE levels, where T cells play a crucial regulatory role. ...
Manufactured by:Akebia Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
Tenacity: At Akebia, we are inspired to think boldly and move bold thinking into action. We leverage our scientific expertise and this innovative thinking to develop clinical advances in areas that are important to people living with kidney disease. We thrive as collaborators because we believe that we can go further together. We work with partners across the globe to pioneer and grow new areas ...
by:MtoZ Biolabs based in, MASSACHUSETTS (USA)
Biosimilars are biological products that are highly similar to an approved original biological drug (reference or brand drug) without any clinically meaningful differences in quality, safety, or efficacy compared to those approved. Biosimilars typically enter the market after the patent protection period of the original drug has expired, providing a more cost-effective treatment ...